Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies

Author:

Sun Wanxiao,Deng Yaxin,Zhao Meihui,Jiang Ying,Gou Jingxin,Wang Yanjiao,Yin Tian,Zhang Yu,He Haibing,Tang Xing

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference263 articles.

1. Cancer Statistics, 2020;Siegel,2020

2. Boo, D.Q.A., et al.., Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment – Sci. Direct. 229.

3. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells;Grieco;J. Cell. Biochem.,2011

4. 68Ga-PSMA-PET/CT in Comparison With 18F-fluoride-PET/CT and Whole-body MRI for the Detection of Bone Metastases in Patients With Prostate Cancer: A Prospective Diagnostic Accuracy Study;Eva,2018

5. Distribution of Metastatic Sites in Patients With Prostate Cancer: A Population-based Analysis;Gandaglia,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3